Health Economics›Acute myeloid leukemia›IDH2 Relapsed or refractory

IDH2 Relapsed or refractory

Acute myeloid leukemia · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine monotherapy Variant #01	IDH	R 29 332	28d	—	~8.7 mo	~6	~R 175 992 PFS proxy · indirect	11
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	IDH	R 1 249	28d	—	4.7 mo	6	R 7 491 PFS proxy	1
Enasidenib monotherapy Variant #01 Partial	IDH	—	28d	—	~6.5 mo	~2	—	1

3 of 3 regimens shown